Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma.
Jialiang CaiLi-Na SongFeng ZhangSuiyi WuGui-Qi ZhuPeiling ZhangShiping ChenJunxian DuBiao WangYufan CaiYi YangJinglei WanJian ZhouJia FanZhi DaiPublished in: Cancer communications (London, England) (2024)
The SRSF10/MYB/glycolysis/lactate axis is critical for triggering immune evasion and anti-PD-1 resistance. Inhibiting SRSF10 by 1C8 may overcome anti-PD-1 tolerance in HCC.